In summary, the results show that increased eNOS-NO signaling is a distinct phenotype of PCSCs and its enhanced activation could function not only to promote the growth of PCSCs but also to advance the malignant growth of prostate cancer via an activation of downstream NO-sGC-cGMP-PKG signaling. The gene discussed is SGCB; the disease is prostate cancer.